Testing INR731 for Metastatic Prostate Cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer that has spread beyond the prostate (metastatic disease) confirmed by imaging
- Your testosterone level is very low (castrate level), either from surgery, ongoing hormone therapy, or injections
- You are at least 18 years old and in good enough health to tolerate the study (ECOG performance status 2 or better)
- Your cancer has either progressed despite other treatments, or you are not eligible for standard treatments
- You have not been treated with certain newer prostate cancer drugs called cereblon degraders before
- You are willing to stop any heart rhythm medications that could interfere with this drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests a prostate cancer treatment plan chosen using your tumor’s biomarker results. It aims to improve outcomes for men with metastatic prostate cancer starting first systemic treatment.
This trial tests two investigational drugs together for men with a type of advanced prostate cancer that has stopped responding to standard hormone therapy. The goal is to see if the combination can shrink tumors or slow the cancer's growth.
This trial tests a new investigational medicine (TY-302) combined with abiraterone, a standard hormone-blocking drug, in men with metastatic castration-resistant prostate cancer. It aims to see if this combination can slow cancer growth after initial hormone therapy stops working.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new experimental drug (TYK-00540) combined with enzalutamide, an approved hormone therapy, for men with advanced prostate cancer that has spread and no longer responds to standard hormone therapy. The goal is to see if the combination can slow cancer growth better than current options.
Hear when a new Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.